Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination
Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively control relapsing conditions, they fail to avert progressive neuroinflammation, neurodegeneration, and remyelination failure. This review offers an evidence-based recontextualization....